Clinical trials
Esophagogastric Adenocarcinoma clinical trials
Below are recruiting esophagogastric adenocarcinoma clinical trials, each written for real people, not researchers. We’re tracking 27 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07059299RecruitingPhase 1
Immunotherapy plus chemo before stomach/esophagus cancer surgery
This trial tests adding an immunotherapy drug (tislelizumab) to standard chemotherapy (FLOT) before surgery for people with stomach or esophagus cancer that can be removed but hasn't spread. The goal is to see if this combination is safe and works better than chemotherapy alone.
FrankfurtAges 18 years+ - NCT05715931RecruitingPhase 2
Surgery chemotherapy plus anti-HER2 and anti–immune therapy for HER2 stomach cancer
This Phase 2 trial tests adding chemotherapy plus trastuzumab and toripalimab around the time of surgery for HER2-positive, locally advanced stomach or esophagus-stomach junction cancer. It aims to shrink the cancer and reduce the chance it comes back by attacking it through more than one pathway.
Hangzhou, ZhejiangAges 18–80 - NCT05729646RecruitingPhase 2
Pre-surgery chemotherapy with toripalimab for dMMR stomach cancer
This trial studies whether adding toripalimab (an immune therapy) to chemotherapy before and around surgery can improve outcomes for people with certain mismatch repair–deficient stomach cancers. It mainly targets tumors that are dMMR and not HER2-positive.
Hangzhou, ZhejiangAges 18–80 - NCT05170503RecruitingPhase 2
Immunotherapy plus chemo before surgery for junction stomach cancers
This Phase 2 study tests giving immunotherapy together with chemotherapy before surgery for certain “locally advanced” cancers at the esophagus-stomach junction. It may help shrink the tumor and improve outcomes by treating the cancer earlier with both immune and chemotherapy approaches.
Guangzhou, GuangdongAges 18–75 - NCT06623396RecruitingPhase 1
CAR T-cell therapy for stomach and esophagus cancer
This trial tests a new treatment called CAR T-cell therapy that targets a protein called mesothelin found on some cancer cells. It is for people with advanced or recurrent cancer of the stomach or esophagus that has spread or come back after prior treatment.
Basking Ridge, New JerseyAges 18 years+ - NCT05978050RecruitingPhase 3
Nimotuzumab plus paclitaxel for recurring stomach cancer
This Phase 3 trial tests whether adding nimotuzumab (an anti-EGFR antibody) to paclitaxel can improve outcomes for people with stomach or stomach-junction cancer that has returned and spread. It targets tumors with high EGFR (“EGFR high” on a pathology test) to see if this combination works better than standard treatment.
Guangzhou, GuangdongAges 18–75 - NCT07441785Recruiting
Comparing stomach reconstruction types after upper stomach cancer surgery
This study compares different ways to rebuild the digestive tract after removing the upper part of the stomach for cancer. It aims to find which method works best for eating and quality of life.
MoscowAges 18 years+ - NCT06340711RecruitingPhase 2
Gene therapy plus Keytruda for advanced stomach or esophageal cancer
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
New York, New YorkAges 18 years+ - NCT05356520Recruiting
Which operation is best for Siewert type II stomach cancer
This trial compares different surgical approaches for removing Siewert type II cancer at the esophagus–stomach junction. It aims to find which operation works best for people who can have the tumor removed.
Xi'an, ShaanxiAges 18–75 - NCT06761846RecruitingPhase 2
Immunotherapy and chemo after stomach cancer surgery
This trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy after surgery can help prevent stage III stomach or gastroesophageal junction cancer from coming back. You may qualify if you had D2 surgery and your tumor tested positive for PD-L1.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06482788RecruitingPhase 2
Immunotherapy plus chemo before & after junction cancer surgery
This trial tests giving an immunotherapy drug (adebrelimab) along with two chemotherapy drugs (capecitabine and oxaliplatin) before and after surgery for a specific type of stomach-cancer junction tumor. It aims to see if this combination is safe and effective in shrinking the tumor and improving outcomes.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT07569068RecruitingPhase 2
Combination Cancer Drugs Before Surgery for Stomach Cancer
This trial tests whether giving immunotherapy and chemotherapy drugs before surgery can help treat stomach cancer that has a specific protein marker (claudin 18.2). The goal is to shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Shanghai, Huangpu DistrictAges 18 years+ - NCT06461910RecruitingPhase 2
Immunotherapy, thymalfasin, and chemo before surgery for stomach cancer
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
Nanjing, JiangsuAges 18–75 - NCT05872685RecruitingPhase 2
Perioperative chemo plus serplulimab for specific stomach cancers
This Phase 2 trial tests whether adding serplulimab (an immune medicine) to standard chemotherapy before and/or around surgery can improve outcomes for people with certain locally advanced stomach cancer. You may get serplulimab or a placebo, and researchers will compare results to see if the immune add-on helps.
Hangzhou, ZhejiangAges 18–80 - NCT04219137Recruiting
MOCHA study of blood and biopsy features in stomach tumors
This study looks at the “molecular” features (biologic characteristics) of gastroesophageal cancer from tissue samples. It may help doctors better understand which cancers are best matched to treatment plans and future therapies.
Toronto, OntarioAges 18 years+ - NCT06644352Recruiting
Comparing right vs. left chest surgery for junction cancer
This study compares two surgical approaches (right side of the chest vs. left side of the chest) for removing a certain type of cancer at the gastroesophageal junction. It aims to find which approach leads to better outcomes.
BeijingAges 18–80 - NCT04989985RecruitingPhase 2
SOX chemotherapy plus immunotherapy for junction stomach-esophagus cancer
This trial studies whether adding an immunotherapy drug (sintilimab) to standard chemotherapy (S-1 and oxaliplatin) can better treat locally advanced cancer at the junction of the esophagus and stomach. It may help shrink the tumor and control the cancer before or around surgery.
Guangzhou, GuangdongAges 18–75 - NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT04656041RecruitingPhase 2
Test chemo with radiation for gastroesophageal cancer
This Phase 2 study tests a combination of chemotherapy (5-FU/leucovorin plus irinotecan and oxaliplatin) together with radiation for certain types of esophagus/stomach-junction cancer. It may help shrink tumors and control cancer that is locally advanced but not spread to distant organs.
Boston, MassachusettsAges 18 years+ - NCT06550063Recruiting
HER2 status in esophagogastric cancer and patient outcomes
This study looks back at medical records of people with a certain type of esophageal or stomach cancer to see how HER2 status relates to patient outcomes. It may help guide future treatment decisions.
Dublin, LeinsterAges Any age - NCT07556640RecruitingPhase 2
Drug combination for stomach cancer with abdominal spread
This trial tests a combination of chemotherapy drugs (LM-302, S-1, and paclitaxel) with or without an immune-boosting drug (cadonilimab) for gastric cancer that has spread to the abdominal lining. The goal is to shrink tumors and improve survival in patients whose cancer cells show a specific protein marker called Claudin 18.2.
Shanghai, Huangpu DistrictAges 18 years+ - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT06300879Recruiting
New surgery technique for upper stomach or junction cancer
This study tests a new surgical technique for removing cancer in the upper stomach or where the stomach meets the esophagus. It aims to see if this technique is safe and effective for people with early-stage adenocarcinoma who haven't had other cancer treatments.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Esophagogastric Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for esophagogastric adenocarcinoma?
- Yes. Clin2 currently lists 27 recruiting esophagogastric adenocarcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a esophagogastric adenocarcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a esophagogastric adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Adenocarcinoma of Esophagogastric Junction
- Gastric or Esophagogastric Junction Adenocarcinoma
- Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Gastric Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- Pancreatic Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.